News for Seres Therapeutics, Inc. (MCRB)

Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Se

Seres Therapeutics (MCRB) is set to showcase new exploratory biomarker data from its SER-155 Phase 1b study at the upcoming 2025 American Society of Clinical On

Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hem

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call May 7, 2025 8:30 AM ETCompany ParticipantsCarlo Tanzi - Investor RelationsEric Shaff -...

Seres Therapeutics (MCRB) is prioritizing the advancement of its treatment, SER-155, into the next phase of clinical development. According to Eric Shaff, the c

**media[617233]**

Seres Therapeutics (MCRB) is set to showcase three related posters at the 2025 Digestive Disease Week Conference, taking place from May 3-6 in San Diego, CA. Th

**media[608640]**

**media[602800]**

U.S. stocks were higher, with the Dow Jones index gaining around 600 points on Tuesday. Shares of Quest Diagnostics Incorporated DGX rose sharply during Tuesda...

**media[568275]**

Net Loss (Q4 2024): $15.7 million, compared to $34.7 million in Q4 2023.Net Loss (Full Year 2024): $125.8 million, compared to $190.1 million in 2023.R&D Expen

Mar 13, 2025 / 12:30PM GMTOperator Thank you for standing by. My name is Kate and I will be your conference operator today. At this time, I would like to welcom

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ETCompany ParticipantsCarlo Tanzi - Kendall Investor...

The following slide deck was published by Seres Therapeutics, Inc.

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- ”¯Seres Therapeutics, Inc.”¯( MCRB), a leading live biotherapeutics company, today announced that manag

FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduc